Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of nivolumab + ipilimumab or nivolumab + chemotherapy versus chemotherapy in previously untreated advanced or metastatic gastric, gastroesophageal junction, or distal esophageal adenocarcinoma
CTR20170371Phase 3Active
- Sponsor
- Bristol Myers Squibb
- Start
- Jul 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of nivolumab in gastric cancer (GC), gastroesophageal junction adenocarcinoma, esophageal adenocarcinoma (EAC), sponsored by Bristol Myers Squibb. Started Jul 2019; status: active.
02
Drugs
03
Conditions
gastric cancer (GC)gastroesophageal junction adenocarcinomaesophageal adenocarcinoma (EAC)
Beyond the preview
Go deeper on CTR20170371.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20170371.